Designation of Canakinumab (Ilaris) as an Orphan Drug - Novartis Pharmaceuticals Australia Pty Limited

Overview

The Therapeutic Goods Regulations 1990 were amended in 2012 to include the designation of orphan drugs, addressing a gap in the availability and development of treatments for rare diseases. This legislative action was introduced by the Australian Parliament, aiming to incentivise the research, development, and availability of treatments for rare conditions that affect a small number of people. The designation of canakinumab (ILARIS) as an orphan drug on 12 November 2012 by Dr Anthony Gill, acting as the Delegate of the Secretary, under the authority of the Therapeutic Goods Regulations 1990, is a direct application of this policy. The purpose of this designation is to support the treatment of rare diseases such as Cryopyrin Associated Periodic Syndromes (CAPS) in both adults and children, including specific syndromes like Muckle-Wells Syndrome, Familial Cold-induced Auto inflammatory Syndrome, and Neonatal-Onset Multisystem Inflammatory Disease.

Scope and Application

The designation of canakinumab (ILARIS) as an orphan drug under the Therapeutic Goods Regulations 1990 applies to the therapeutic use of this medication for the treatment of specific rare diseases known as Cryopyrin Associated Periodic Syndromes (CAPS), which include Muckle-Wells Syndrome, Familial Cold-induced Autoinflammatory Syndrome, Neonatal-Onset Multisystem Inflammatory Disease, and Chronic Infantile Neurological Cutaneous and Articular syndrome. This designation is relevant to both adults and children aged two years and older, and the medication is available in a powder for injection form. The sponsor of this drug is Novartis Pharmaceuticals Australia Pty Limited, and the designation was officially made by Dr Anthony Gill, acting as the Delegate of the Secretary on 12 November 2012. This legislative action underscores the Commonwealth's commitment to supporting the development and availability of treatments for rare and debilitating conditions. While the primary application of this Act is to the pharmaceutical industry and healthcare providers involved in the treatment of CAPS, it also indirectly affects patients, caregivers, and health insurance entities through its regulation of the therapeutic goods market.

Key Provisions

The key operative sections of this legislation are contained in the notification issued by Dr. Anthony Gill, the Delegate of the Secretary, who designates canakinumab (ILARIS) as an orphan drug for specific medical conditions (s. 16J (2) of the Therapeutic Goods Regulations 1990). This designation is for the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in both adults and children aged two years and older, including Muckle-Wells Syndrome (MWS), Familial Cold-induced Autoinflammatory Syndrome (FCAS)/Familial Cold Urticaria (FCU), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID)/Chronic Infantile Neurological Cutaneous and Articular syndrome (CINCA). The drug is available in the form of powder for injection, and the sponsor for canakinumab (ILARIS) is Novartis Pharmaceuticals Australia Pty Limited. This designation took effect on 12 November 2012. The Act imposes specific obligations on the parties involved, primarily focusing on the sponsor, Novartis Pharmaceuticals Australia Pty Limited. This sponsor is responsible for ensuring that canakinumab (ILARIS) is manufactured, stored, and distributed in compliance with the Therapeutic Goods Regulations 1990. The sponsor must also ensure that the drug is safe and effective for the designated indications, and that all necessary documentation and approvals are obtained and maintained. Additionally, the sponsor is required to report any adverse effects or issues related to the drug to the appropriate regulatory authorities. The legislation does not explicitly state the penalties or consequences for breach, but violations of the Therapeutic Goods Regulations 1990 can result in significant civil and criminal consequences. Under the Therapeutic Goods Act 1989, breaches of the regulations can lead to fines, imprisonment, or both. The maximum penalties can vary depending on the specific offence and the circumstances, but they can include fines of up to $1,650,000 for corporations and imprisonment for up to 10 years. Furthermore, the Therapeutic Goods Administration (TGA) has the authority to take enforcement actions such as product recalls, suspension or cancellation of permits, and public warnings. In summary, the designation of canakinumab (ILARIS) as an orphan drug under the Therapeutic Goods Regulations 1990 is a significant step in making this treatment available for patients suffering from rare and debilitating conditions. The sponsor, Novartis Pharmaceuticals Australia Pty Limited, has the primary responsibility of ensuring compliance with the regulations, and failure to do so can result in severe penalties, including substantial fines and imprisonment.